Literature DB >> 18990174

The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.

Necole M Streeper1, Christopher M Simons, Badrinath R Konety, DeSirae M Muirhead, Richard D Williams, Michael A O'Donnell, Fadi N Joudi.   

Abstract

OBJECTIVE: To test the hypothesis that patients with bladder cancer who had evidence of lymphovascular invasion (LVI) in their transurethral resection of bladder tumour (TURBT) and radical cystectomy (RC) specimens would have a worse prognosis and higher likelihood of clinical understaging, and to assess the effect of LVI discovered at RC on subsequent disease-related mortality, as the prognostic significance of LVI in TURBT or RC specimens of patients treated for urothelial carcinoma of the bladder is not completely established. PATIENTS AND METHODS: We retrospectively reviewed the records of 163 patients with urothelial carcinoma of the bladder seen at our institution, and who had TURBT (69) or RC (94) between 1995 and 2005. We compared patients with LVI on TURBT and/or RC specimens to a group of controls who did not have LVI on TURBT (34) or RC (32).
RESULTS: Patients with LVI present in their TURBT specimen had a shorter disease-specific survival than those without LVI, with a 5-year survival of 33.6% vs 62.9% (log-rank test P = 0.027; hazard ratio 2.21). LVI at TURBT varied with clinical stage (P = 0.049). Patients with LVI and who were clinical stage I or II had lower survival than those without LVI (P = 0.049; hazard ratio 2.68). LVI did not affect survival among those with clinical stage III or IV (P = 0.29). There was a trend for patients with LVI at TURBT to be clinically understaged compared to those without LVI (75% vs 46%) but the difference was not significant (P = 0.086). Patients with LVI detected in their RC specimen were significantly more likely to have cancer recurrence than were those with no evidence of LVI (48% vs 19%, P = 0.006). For the RC group there was also a significant difference in survival distribution between patients with evidence of LVI vs those without (5-year survival 45.5% vs 78.4%, P = 0.017). Those with LVI were significantly more likely to die from the disease than those without LVI (P = 0.017; hazard ratio 2.92).
CONCLUSIONS: Our findings suggest that LVI is a histological feature that might be associated with a poorer prognosis in patients with urothelial carcinoma of the bladder. The presence of LVI in TURBT specimens predicts shorter survival for patients with stage I or II disease. The presence of LVI in RC specimens predicts recurrence of disease and shorter survival. Further studies are needed to determine whether this group of patients would benefit from early RC and/or perioperative chemotherapy to improve clinical outcomes.

Entities:  

Mesh:

Year:  2008        PMID: 18990174     DOI: 10.1111/j.1464-410X.2008.08011.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  21 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 2.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.

Authors:  Romain Mathieu; Ilaria Lucca; Morgan Rouprêt; Alberto Briganti; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2016-07-19       Impact factor: 14.432

3.  Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.

Authors:  Venu Chalasani; Wassim Kassouf; Joseph L Chin; Yves Fradet; Armen G Aprikian; Adrian S Fairey; Eric Estey; Louis Lacombe; Ricardo Rendon; David Bell; Ilias Cagiannos; Darrell Drachenberg; Jean-Baptiste Lattouf; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

Review 4.  [Current developments in the diagnostics and therapy of bladder carcinoma].

Authors:  J Kamradt; C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

5.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

6.  Prognostic significance of lymphovascular invasion in bladder cancer after surgical resection: A meta-analysis.

Authors:  Yuan-Feng Tian; Hui Zhou; Gan Yu; Ji Wang; Heng Li; Ding Xia; Hai-Bing Xiao; Ji-Hong Liu; Zhang-Qun Ye; Hua Xu; Qian-Yuan Zhuang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

Review 7.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

8.  Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Authors:  Michael J Metcalfe; James E Ferguson; Roger Li; Lianchun Xiao; Charles C Guo; Bogdan A Czerniak; Arlene Siefker-Radtke; Shanna M Pretzsch; Neema Navai; David J McConkey; Ashish M Kamat; Mathew Campbell; Colin Dinney
Journal:  Eur Urol Focus       Date:  2017-07-13

Review 9.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

10.  [Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery?].

Authors:  M May; M Burger; S Brookman-May; W Otto; J Peter; O Rud; H-M Fritsche; C Bolenz; L Trojan; E Herrmann; M S Michel; C Wülfing; R Moritz; A Tiemann; S C Müller; J Ellinger; A Buchner; C G Stief; D Tilki; W F Wieland; C Gilfrich; T Höfner; M Hohenfellner; A Haferkamp; J Roigas; P Bretschneider-Ehrenberg; O Müller; M Zacharias; S Gunia; P J Bastian
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.